Tiziana Life Sciences Shares Drop Despite Positive Phase 2a Results for Foralumab
Tiziana Life Sciences (TLSA) shares fell approximately 13% during Monday trading following the release of mid-stage clinical data. Although the company reported that its intranasal foralumab met both primary endpoints in a Phase 2a study for patients with non-active secondary progressive multiple sclerosis, the market reacted negatively to the news. The clinical results demonstrated a statistically significant reduction in neuroinflammation after 12 weeks of treatment. Despite meeting these key efficacy milestones, investor sentiment appears to have been impacted by other factors or expectations surrounding the asset's development path.
Tickers: $TLSA
Topics: biotechnology clinical trial results multiple sclerosis stock price movement
Read the full article at Seeking Alpha
Part of the story Tiziana Life Sciences Shares Drop Despite Positive Phase 2a Results for Foralumab (2 articles)